Thymosin Alpha-1 (TA1)

5mg Vial

10mg Vial

29 August 2026Updated 29 August 2026

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Thymosin Alpha-1 (TA1).

Create free account Member login

Full range of benefits for Thymosin Alpha-1 (TA1)

Enhances T-cell maturation and function

Promotes dendritic cell activation and antigen presentation

Increases natural killer (NK) cell activity

Augments cytokine responses, including interferon-gamma

Acts as an adjuvant to improve vaccine responses

Adjunctive therapy in chronic viral infections (eg, HBV/HCV)

May reduce infection risk in immunocompromised patients

Supports lymphocyte recovery after chemotherapy or immunosuppression

Modulates immune inflammation toward balanced responses

Demonstrated favourable safety and tolerability in clinical studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 14 known interactions

Synergistic(3)Compatible(3)Monitor(4)Avoid(4)

Generally well-tolerated alongside this peptide

Acetaminophen (paracetamol)

No known pharmacodynamic or pharmacokinetic interaction with TA1; can be used for symptomatic relief without special adjustments.

Broad-spectrum antibiotics (e.g., beta-lactams)

Antibacterial agents do not have direct interactions with TA1 and are generally safe to co-administer to treat concurrent infections.

Statins (HMG-CoA reductase inhibitors)

No significant interaction expected between statins and TA1, so chronic lipid-lowering therapy can usually be continued with routine monitoring.

All interaction categories

Synergistic (3)

Interferon-alpha (including pegylated forms): Thymosin alpha-1 has been shown to enhance antiviral and immunomodulatory effects when combined with interferon-alpha, improving viral clearance and immune responses in some hepatic and oncologic settings.
PD-1/PD-L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab): TA1 can augment antigen-specific T‑cell responses and may potentiate the efficacy of checkpoint inhibitors by enhancing T‑cell function and tumor immunogenicity.
Therapeutic and prophylactic vaccines (non-live and some adjuvanted vaccines): TA1 acts as an immunoadjuvant that can increase vaccine-induced cellular and humoral responses, improving seroconversion and T‑cell activation rates.

Compatible (3)

Acetaminophen (paracetamol): No known pharmacodynamic or pharmacokinetic interaction with TA1; can be used for symptomatic relief without special adjustments.
Broad-spectrum antibiotics (e.g., beta-lactams): Antibacterial agents do not have direct interactions with TA1 and are generally safe to co-administer to treat concurrent infections.
Statins (HMG-CoA reductase inhibitors): No significant interaction expected between statins and TA1, so chronic lipid-lowering therapy can usually be continued with routine monitoring.

Monitor (4)

Systemic corticosteroids (e.g., prednisone): Corticosteroids may blunt the immunostimulatory effects of TA1 and clinical immune endpoints should be monitored with attention to timing and dose adjustments.
Calcineurin inhibitors (cyclosporine, tacrolimus): Concurrent use may alter the balance between immunosuppression and activation—monitor graft function, drug levels where applicable, and immune markers in transplant patients.
Immune checkpoint inhibitors and other immunotherapies: Although potentially synergistic, combined therapy increases the risk of immune-related adverse events and requires close monitoring for autoimmune toxicity and organ dysfunction.
Hepatotoxic medications or antivirals with hepatic risk: When TA1 is used in populations with liver disease or alongside hepatotoxic agents, monitor liver function tests periodically due to overlapping hepatic risk profiles in clinical practice.

Avoid (4)

Active autoimmune disease: TA1's immune-stimulatory properties may exacerbate underlying autoimmune disorders, so use requires specialist assessment and risk–benefit consideration.
Solid organ transplant recipients: Immune activation from TA1 could increase the risk of graft rejection, necessitating careful multidisciplinary evaluation before initiation.
Live attenuated vaccines: Co-administration may heighten reactogenicity or alter vaccine safety/efficacy profiles, so timing and necessity should be carefully evaluated.
Concurrent high‑dose cytokine therapies (e.g., IL-2, IFN‑gamma): Combining TA1 with potent immunostimulatory cytokines may increase the risk of excessive immune activation or cytokine-mediated toxicity and should be approached with caution.